Assessment of the duration of protection in Campylobacter jejuni experimental infection in humans

David R. Tribble, Shahida Baqar, Daniel A. Scott, Michael L. Oplinger, Fernando Trespalacios, David Rollins, Richard I. Walker, John D. Clements, Steven Walz, Paul Gibbs, Edward F. Burg, Anthony P. Moran, Lisa Applebee, Louis Bourgeois

Research output: Contribution to journalArticle

Abstract

A human Campylobacter jejuni infection model provided controlled exposure to assess vaccine efficacy and investigate protective immunity for this important diarrheal pathogen. A well-characterized outbreak strain, C. jejuni 81-176, was investigated using a volunteer experimental infection model to evaluate the dose range and. STV (25% of the subjects were not infected; 3-log-lower maximum excretion level). Systemic and mucosal immune responses were robust in naïve subjects irrespective of the dose or the severity of illness. In contrast, in STV there was a lack of circulating antibody-secreting cells (ASC), reflecting the local mucosal effector responses. LTV exhibited comparable ASC responses to primary infection, and anamnestic fecal IgA responses likely contributed to self-resolving illness prior to antibiotic treatment. Campylobacter antigen-dependent production of gamma interferon by peripheral blood mononuclear cells was strongly associated with protection from illness, supporting the hypothesis that TH1 polarization has a primary role in acquired immunity to C. jejuni. This study revealed a C. jejuni dose-related increase in campylobacteriosis rates, evidence of complete short-term protection that waned with time, and immune response patterns associated with protection.

Original languageEnglish (US)
Pages (from-to)1750-1759
Number of pages10
JournalInfection and Immunity
Volume78
Issue number4
DOIs
StatePublished - Apr 2010
Externally publishedYes

Fingerprint

Campylobacter jejuni
Antibody-Producing Cells
Infection
Campylobacter Infections
Mucosal Immunity
Campylobacter
Adaptive Immunity
Immunoglobulin A
Interferon-gamma
Disease Outbreaks
Volunteers
Immunity
Blood Cells
Theoretical Models
Vaccines
Anti-Bacterial Agents
Antigens
Therapeutics

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Parasitology
  • Infectious Diseases

Cite this

Tribble, D. R., Baqar, S., Scott, D. A., Oplinger, M. L., Trespalacios, F., Rollins, D., ... Bourgeois, L. (2010). Assessment of the duration of protection in Campylobacter jejuni experimental infection in humans. Infection and Immunity, 78(4), 1750-1759. https://doi.org/10.1128/IAI.01021-09

Assessment of the duration of protection in Campylobacter jejuni experimental infection in humans. / Tribble, David R.; Baqar, Shahida; Scott, Daniel A.; Oplinger, Michael L.; Trespalacios, Fernando; Rollins, David; Walker, Richard I.; Clements, John D.; Walz, Steven; Gibbs, Paul; Burg, Edward F.; Moran, Anthony P.; Applebee, Lisa; Bourgeois, Louis.

In: Infection and Immunity, Vol. 78, No. 4, 04.2010, p. 1750-1759.

Research output: Contribution to journalArticle

Tribble, DR, Baqar, S, Scott, DA, Oplinger, ML, Trespalacios, F, Rollins, D, Walker, RI, Clements, JD, Walz, S, Gibbs, P, Burg, EF, Moran, AP, Applebee, L & Bourgeois, L 2010, 'Assessment of the duration of protection in Campylobacter jejuni experimental infection in humans', Infection and Immunity, vol. 78, no. 4, pp. 1750-1759. https://doi.org/10.1128/IAI.01021-09
Tribble DR, Baqar S, Scott DA, Oplinger ML, Trespalacios F, Rollins D et al. Assessment of the duration of protection in Campylobacter jejuni experimental infection in humans. Infection and Immunity. 2010 Apr;78(4):1750-1759. https://doi.org/10.1128/IAI.01021-09
Tribble, David R. ; Baqar, Shahida ; Scott, Daniel A. ; Oplinger, Michael L. ; Trespalacios, Fernando ; Rollins, David ; Walker, Richard I. ; Clements, John D. ; Walz, Steven ; Gibbs, Paul ; Burg, Edward F. ; Moran, Anthony P. ; Applebee, Lisa ; Bourgeois, Louis. / Assessment of the duration of protection in Campylobacter jejuni experimental infection in humans. In: Infection and Immunity. 2010 ; Vol. 78, No. 4. pp. 1750-1759.
@article{951386d08bab45f6a7a77e30be5521d7,
title = "Assessment of the duration of protection in Campylobacter jejuni experimental infection in humans",
abstract = "A human Campylobacter jejuni infection model provided controlled exposure to assess vaccine efficacy and investigate protective immunity for this important diarrheal pathogen. A well-characterized outbreak strain, C. jejuni 81-176, was investigated using a volunteer experimental infection model to evaluate the dose range and. STV (25{\%} of the subjects were not infected; 3-log-lower maximum excretion level). Systemic and mucosal immune responses were robust in na{\"i}ve subjects irrespective of the dose or the severity of illness. In contrast, in STV there was a lack of circulating antibody-secreting cells (ASC), reflecting the local mucosal effector responses. LTV exhibited comparable ASC responses to primary infection, and anamnestic fecal IgA responses likely contributed to self-resolving illness prior to antibiotic treatment. Campylobacter antigen-dependent production of gamma interferon by peripheral blood mononuclear cells was strongly associated with protection from illness, supporting the hypothesis that TH1 polarization has a primary role in acquired immunity to C. jejuni. This study revealed a C. jejuni dose-related increase in campylobacteriosis rates, evidence of complete short-term protection that waned with time, and immune response patterns associated with protection.",
author = "Tribble, {David R.} and Shahida Baqar and Scott, {Daniel A.} and Oplinger, {Michael L.} and Fernando Trespalacios and David Rollins and Walker, {Richard I.} and Clements, {John D.} and Steven Walz and Paul Gibbs and Burg, {Edward F.} and Moran, {Anthony P.} and Lisa Applebee and Louis Bourgeois",
year = "2010",
month = "4",
doi = "10.1128/IAI.01021-09",
language = "English (US)",
volume = "78",
pages = "1750--1759",
journal = "Infection and Immunity",
issn = "0019-9567",
publisher = "American Society for Microbiology",
number = "4",

}

TY - JOUR

T1 - Assessment of the duration of protection in Campylobacter jejuni experimental infection in humans

AU - Tribble, David R.

AU - Baqar, Shahida

AU - Scott, Daniel A.

AU - Oplinger, Michael L.

AU - Trespalacios, Fernando

AU - Rollins, David

AU - Walker, Richard I.

AU - Clements, John D.

AU - Walz, Steven

AU - Gibbs, Paul

AU - Burg, Edward F.

AU - Moran, Anthony P.

AU - Applebee, Lisa

AU - Bourgeois, Louis

PY - 2010/4

Y1 - 2010/4

N2 - A human Campylobacter jejuni infection model provided controlled exposure to assess vaccine efficacy and investigate protective immunity for this important diarrheal pathogen. A well-characterized outbreak strain, C. jejuni 81-176, was investigated using a volunteer experimental infection model to evaluate the dose range and. STV (25% of the subjects were not infected; 3-log-lower maximum excretion level). Systemic and mucosal immune responses were robust in naïve subjects irrespective of the dose or the severity of illness. In contrast, in STV there was a lack of circulating antibody-secreting cells (ASC), reflecting the local mucosal effector responses. LTV exhibited comparable ASC responses to primary infection, and anamnestic fecal IgA responses likely contributed to self-resolving illness prior to antibiotic treatment. Campylobacter antigen-dependent production of gamma interferon by peripheral blood mononuclear cells was strongly associated with protection from illness, supporting the hypothesis that TH1 polarization has a primary role in acquired immunity to C. jejuni. This study revealed a C. jejuni dose-related increase in campylobacteriosis rates, evidence of complete short-term protection that waned with time, and immune response patterns associated with protection.

AB - A human Campylobacter jejuni infection model provided controlled exposure to assess vaccine efficacy and investigate protective immunity for this important diarrheal pathogen. A well-characterized outbreak strain, C. jejuni 81-176, was investigated using a volunteer experimental infection model to evaluate the dose range and. STV (25% of the subjects were not infected; 3-log-lower maximum excretion level). Systemic and mucosal immune responses were robust in naïve subjects irrespective of the dose or the severity of illness. In contrast, in STV there was a lack of circulating antibody-secreting cells (ASC), reflecting the local mucosal effector responses. LTV exhibited comparable ASC responses to primary infection, and anamnestic fecal IgA responses likely contributed to self-resolving illness prior to antibiotic treatment. Campylobacter antigen-dependent production of gamma interferon by peripheral blood mononuclear cells was strongly associated with protection from illness, supporting the hypothesis that TH1 polarization has a primary role in acquired immunity to C. jejuni. This study revealed a C. jejuni dose-related increase in campylobacteriosis rates, evidence of complete short-term protection that waned with time, and immune response patterns associated with protection.

UR - http://www.scopus.com/inward/record.url?scp=77950230080&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950230080&partnerID=8YFLogxK

U2 - 10.1128/IAI.01021-09

DO - 10.1128/IAI.01021-09

M3 - Article

C2 - 20086085

AN - SCOPUS:77950230080

VL - 78

SP - 1750

EP - 1759

JO - Infection and Immunity

JF - Infection and Immunity

SN - 0019-9567

IS - 4

ER -